Development and validation of a stability-indicating LC-UV method for rapid analysis of buspirone in pharmaceutical dosage forms

• Autorzy: Azeem A. , Rizwan M. , Ahmad F. J. , Iqbal Z. , Khar R. K. , Aqil M , Talegaonkar S.
• Języki publikacji: EN

Abstrakty

EN

An accurate, sensitive, precise, rapid and isocratic reversed-phase HPLC (RPHPLC) method for analysis of buspirone in the bulk drug and in solid dosage formulations has been developed and validated. The best separation was achieved on a 250 mm × 4.6 mm i.d., 5-μm particle, RP C 18 column with 70:30 ( υ/υ ) methanol-0.01 M sodium dihydrogen phosphate buffer (pH 3.5) as mobile phase at a flow rate of 0.8 mL min ^-1. UV detection was at 244 nm. Response was a linear function of concentration over the range 0.05–20 μg mL ^-1 ( r = 0.9998) and the limits of detection and quantitation were 3.7 and 11.3 ng mL ^-1, respectively. The method was validated in accordance with ICH guidelines. The drug was subjected to oxidative, hydrolytic, photolytic, and thermal stress. Degradation products produced as a result of this stress did not interfere with detection of buspirone and the assay can thus be regarded as stability-indicating. The method was used for quantification of buspirone in commercial buspirone tablets and to check content uniformity. The excipients present in the formulation did not interfere with the assay. The method is suitable for application in quality-control laboratories, because it is simple and rapid with good accuracy and precision.

Słowa kluczowe

EN

buspirone; reversed-phase HPLC; validation; assay; quality control; stability-indicating method; forced degradation studies

• Wydawca: University of Silesia in Katowice ; Akademiai Kiado
• Czasopismo: Acta Chromatographica
• Rocznik: 2009
• Tom: Vol. 21, no. 2
• Strony: 283--297
• Opis fizyczny: Bibliogr. 36 poz., rys., tab.

Twórcy

autor

Azeem A.

• Faculty of Pharmacy Department of Pharmaceutics Jamia Hamdard, New Delhi 110062 India

autor

Rizwan M.

• Faculty of Pharmacy Department of Pharmaceutics Jamia Hamdard, New Delhi 110062 India

autor

Ahmad F. J.

• Faculty of Pharmacy Department of Pharmaceutics Jamia Hamdard, New Delhi 110062 India

autor

Iqbal Z.

• Faculty of Pharmacy Department of Pharmaceutics Jamia Hamdard, New Delhi 110062 India

autor

Khar R. K.

• Faculty of Pharmacy Department of Pharmaceutics Jamia Hamdard, New Delhi 110062 India

autor

Aqil M

• Faculty of Pharmacy Department of Pharmaceutics Jamia Hamdard, New Delhi 110062 India

autor

Talegaonkar S.

• Faculty of Pharmacy Department of Pharmaceutics Jamia Hamdard, New Delhi 110062 India

Bibliografia

• [1] A.S. Eison and D.L. Temple, Am. J. Med., 80 , 1 (1986)
• [2] K.L. Goa and A. Ward, Drugs, 32 , 114 (1986)
• [3] H. Goldberg, Pharmacotherapy, 4 , 315 (1994)
• [4] R. Krysiak, E. Obuchowicz, and Z.S. Herman, Neur. Res., 51 , 924 (1986)
• [5] Z. Chilmonckyk, H. Ksycinska, J. Cybulski, and A. Wozniakowska-Szelejewska, Die Pharm., 51 , 924 (1986)
• [6] A. Gobert, A. Newman-Tancredi, J.M. Rivet, V. Audinot, and M.J. Millan, Eur. Neuropyschopharmacol., 7 , S149 (1997)
• [7] S.M. Fouroton, A. Zarghi, A.R. Shafaati, and A. Khoddam, Farmaco, 59 , 739 (2004)
• [8] X. Aparicio, A. Campos, J. Gras, E. Fernandez, and E. Gelpi, J. Pharm. Biomed. Anal., 6 , 945 (1988)
• [9] P. Betto, A. Meneguz, G. Ricciarello, E. Fernandez, and C. Pichini, J. Chromatogr., 575 , 117 (1992)
• [10] M. Franklin, J. Chromatogr., 526 , 590 (1990)
• [11] J. Odontiadis and M. Franklin, J. Pharm. Biomed. Anal., 14 , 347 (1996)
• [12] W.M. Chew, M-J. Xu, C.A. Cordova, and H-H. Sherrychow, J. Chromatogr. B, 844 , 25 (2006)
• [13] S-H. Cho, H-W. Lee, H-T. Im, W-S. Park, Y-W. Choi, J-H. Rew, and K-T. Lee, Rapid Commun. Mass Spectrom., 20 , 1293, (2006)
• [14] E. Nagele and A.S. Fandino, J. Chromatogr. A, 1156 , 196 (2007)
• [15] J.W. Hager and J.C. YvesLeBlanc, J. Chromatogr. A, 1020 , 3 (2003)
• [16] F. Kristjannson, J. Chromatogr., 566 , 250 (1991)
• [17] T.H. Tsai and C.F. Chen, J. Chromatogr. A, 762 , 269 (1997)
• [18] E.H. Kerns, R.A. Routick, K.J. Volk, and M.S. Lee, J. Chromatogr. B, 698 , 133 (1997)
• [19] C.A. Goldthwaite Jr, F-Y. Hsieh, S.W. Womble, B.J. Noves, and I.A. Blair, Anal. Chem., 68 , 2996 (1996)
• [20] M.G. Quaglia, A. Farina, E. Bossu, and C.D. Aquila, J. Pharm. Biomed. Anal., 13 , 505 (1995)
• [21] S.M. Sabry, M.H. Barary, M.H. Abdel Hay, and T.S. Belal, J. Pharm. Biomed. Anal., 34 , 509 (2004)
• [22] A. Khedr and A. Sekr, J. Chromatogr. Sci., 37 , 462 (1999)
• [23] M. Zaxariou and I. Panderi, J. Pharm. Biomed. Anal., 35 , 41 (2004)
• [24] Z. Plotkowiak, J. Cybulski, M. Popielarz-Brzezinska, A. Grzeszkiewicz, I. Centrowska, and A. Kalska-Kowalska, Chem. Anal., 41 , 983 (1996)
• [25] N. Adel-Ghani, Y. Issa, A. Shoukry, and H. Ahmed, Ann. Chim., 97 (2007)
• [26] J.A. Squella, Y. Borges, L. Bobadilla, and L.J. Nunez-Vergara, Electroanal. J., 4 , 333 (1990)
• [27] W.M.A. Niessen, J. Lin, and G.C. Bondoux, J. Chromatogr. A, 970 , 131 (2002)
• [28] RT. Sane, N.L. Chonken, S.R. Surve, M.G. Gangrade, and V.V. Bapat, Indian Drugs, 30 , 235 (1993)
• [29] V.C. Jacob, S.N. Murthy, J. Saravanan, and J. Ravishankar, Indian Drugs, 34 , 24 (1997)
• [30] International Conference on Harmonization (ICH), Validation of Analytical Procedures: Text and Methodology Q2 (R1), November 2005
• [31] S.C. Chow and J. Shao, Statistics in Drug Research: Methodologies and Recent Developments, Marcel Dekker, 2002, pp. 31–52
• [32] M. Zeaiter, J.M. Roger, V.B. Maurel, and D.N. Rutledge, Trends Anal. Chem., 23 , 157 (2004)
• [33] M. Mulholland, Trends Anal. Chem., 7 , 383 (1988)
• [34] ICH, Stability Testing of New Drug Substances and Products (Q1AR). International Conference on Harmonisation, IFPMA, Geneva, 2000
• [35] ICH, Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. International Conference on Harmonisation, IFPMA, Geneva, 1999
• [36] International Conference on Harmonization (ICH), Guidance for Industry, Q1A (R2): Stability Testing of New Drug Substances and Products, IFPMA, Geneva, 2003